RU2018132595A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018132595A3 RU2018132595A3 RU2018132595A RU2018132595A RU2018132595A3 RU 2018132595 A3 RU2018132595 A3 RU 2018132595A3 RU 2018132595 A RU2018132595 A RU 2018132595A RU 2018132595 A RU2018132595 A RU 2018132595A RU 2018132595 A3 RU2018132595 A3 RU 2018132595A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662318014P | 2016-04-04 | 2016-04-04 | |
| US62/318,014 | 2016-04-04 | ||
| US201662378543P | 2016-08-23 | 2016-08-23 | |
| US62/378,543 | 2016-08-23 | ||
| PCT/US2017/025718 WO2017176628A1 (en) | 2016-04-04 | 2017-04-03 | Methods for solid tumor treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018132595A RU2018132595A (ru) | 2020-05-12 |
| RU2018132595A3 true RU2018132595A3 (ru) | 2020-06-22 |
| RU2737934C2 RU2737934C2 (ru) | 2020-12-07 |
Family
ID=58668944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018132595A RU2737934C2 (ru) | 2016-04-04 | 2017-04-03 | Способы лечения солидных опухолей |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US10391090B2 (ru) |
| EP (2) | EP3439635B1 (ru) |
| JP (2) | JP6970683B2 (ru) |
| KR (3) | KR102317108B1 (ru) |
| CN (2) | CN114767860A (ru) |
| AU (2) | AU2017246316B2 (ru) |
| BR (1) | BR112018069628A2 (ru) |
| CA (1) | CA3018989A1 (ru) |
| DK (1) | DK3439635T3 (ru) |
| ES (1) | ES2858092T3 (ru) |
| PT (1) | PT3439635T (ru) |
| RU (1) | RU2737934C2 (ru) |
| SG (2) | SG11201808125RA (ru) |
| WO (1) | WO2017176628A1 (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10751319B2 (en) | 2015-06-04 | 2020-08-25 | Crititech, Inc. | Collection device and methods for use |
| CN108778244B (zh) | 2015-09-16 | 2022-04-01 | Dfb索里亚有限责任公司 | 药物纳米颗粒的递送及其使用方法 |
| WO2017176628A1 (en) | 2016-04-04 | 2017-10-12 | Crititech, Inc. | Methods for solid tumor treatment |
| CN118948828A (zh) | 2017-03-15 | 2024-11-15 | Dfb索里亚有限责任公司 | 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法 |
| CN110730679A (zh) | 2017-06-09 | 2020-01-24 | 克里蒂泰克公司 | 囊内注射抗肿瘤颗粒治疗上皮囊肿 |
| CN110799176A (zh) | 2017-06-14 | 2020-02-14 | 克里蒂泰克公司 | 治疗肺部疾病的方法 |
| RU2020110399A (ru) | 2017-10-03 | 2021-11-09 | Крититек, Инк. | Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака |
| AU2019205916A1 (en) * | 2018-01-05 | 2020-07-02 | Crititech, Inc. | Treatment of bladder cancer by local administration of taxane particles |
| EP3765035A4 (en) | 2018-03-16 | 2021-10-27 | DFB Soria, LLC | TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND COLD CANCER USING TAXANE NANOPARTICLES |
| US20190365698A1 (en) * | 2018-05-31 | 2019-12-05 | Crititech, Inc. | Use of Antineoplastic Agents to Stimulate the Immune System for Treatment of Cancer |
| JP7423544B2 (ja) * | 2018-05-31 | 2024-01-29 | クリティテック・インコーポレイテッド | 養子細胞療法およびがんワクチンのための腫瘍特異的免疫細胞を対象から単離するための方法 |
| WO2019231498A1 (en) | 2018-05-31 | 2019-12-05 | Crititech, Inc. | Treatment of kidney tumors by intratumoral injection of taxane particles |
| WO2020072090A1 (en) * | 2018-10-03 | 2020-04-09 | Crititech, Inc. | Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls) |
| US11439586B2 (en) | 2018-10-16 | 2022-09-13 | US Nano Food & Drug INC | Intratumour injection formulation |
| JP7221378B2 (ja) * | 2019-04-24 | 2023-02-13 | 京セラ株式会社 | ガス検出システム |
| EP4135686A4 (en) * | 2020-04-13 | 2025-03-12 | US Nano Food & Drug Inc | BASIC CHEMOTHERAPEUTIC INTRATUMORAL INJECTION FORMULATION |
| KR20240000560A (ko) * | 2021-04-26 | 2024-01-02 | 크리티테크, 인크. | 시스플라틴 입자 및 이의 용도 |
| KR102712163B1 (ko) | 2022-09-29 | 2024-09-30 | 주식회사 동희산업 | 차량용 고압용기의 고정기구 |
| KR102712164B1 (ko) | 2022-09-29 | 2024-09-30 | 주식회사 동희산업 | 수소탱크 고정장치 |
| KR20250093512A (ko) * | 2022-10-25 | 2025-06-24 | 크리티테크, 인크. | 시스플라틴 입자 및 그의 용도 |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| US5874029A (en) | 1996-10-09 | 1999-02-23 | The University Of Kansas | Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent |
| US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| AU741439B2 (en) | 1996-12-30 | 2001-11-29 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
| EP1023050B1 (en) | 1997-06-27 | 2013-09-25 | Abraxis BioScience, LLC | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6117949A (en) | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| JP3418751B2 (ja) * | 1998-01-22 | 2003-06-23 | 参天製薬株式会社 | フルオロメトロン懸濁型点眼剤 |
| IL131217A0 (en) | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
| US6221153B1 (en) | 1998-06-09 | 2001-04-24 | Trevor Percival Castor | Method for producing large crystals of complex molecules |
| US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| US6113795A (en) | 1998-11-17 | 2000-09-05 | The University Of Kansas | Process and apparatus for size selective separation of micro- and nano-particles |
| CA2351947C (en) | 1998-11-25 | 2008-10-21 | Universitatsklinikum Freiburg | Hyperforin as cytostatic agent and hyperforin ointment or cream as application form |
| US6537585B1 (en) | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
| US7217735B1 (en) | 1999-04-09 | 2007-05-15 | Au Jessie L-S | Methods and compositions for enhancing delivery of therapeutic agents to tissues |
| DE60024811T3 (de) * | 1999-05-27 | 2010-01-07 | Acusphere, Inc., Watertown | Poröse arzneistoffmatrizen und deren herstellungsverfahren |
| CN100376291C (zh) * | 1999-05-27 | 2008-03-26 | 阿库斯菲尔公司 | 多孔药物基质及其制造方法 |
| US6610317B2 (en) * | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US6616849B1 (en) | 1999-08-25 | 2003-09-09 | Shimadzu Corporation | Method of and system for continuously processing liquid materials, and the product processed thereby |
| EP1235598A2 (en) | 1999-11-12 | 2002-09-04 | Angiotech Pharmaceuticals, Inc. | Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
| US6620351B2 (en) | 2000-05-24 | 2003-09-16 | Auburn University | Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer |
| US6562952B1 (en) | 2000-10-31 | 2003-05-13 | The University Of Kansas | Precipitation of proteins from organic solutions |
| US20020081339A1 (en) | 2000-12-22 | 2002-06-27 | Philippe Menei | Treatment of inoperable tumors by stereotactic injection of microspheres |
| US20020192280A1 (en) | 2001-05-01 | 2002-12-19 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents |
| EP1401563B2 (en) | 2001-07-02 | 2015-09-16 | Micro & Nano Materials SAGL | Process for the production of micro and/or nano particles |
| US20030054042A1 (en) | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| US20030134810A1 (en) | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
| JP2005508354A (ja) | 2001-10-15 | 2005-03-31 | クリチテック インコーポレーテッド | 水に溶けにくい薬物の送込み用組成物および方法並びに治療方法 |
| AU2002364701B8 (en) | 2001-11-20 | 2006-06-22 | Alkermes, Inc. | Compositions for sustained action product delivery |
| US7138136B2 (en) | 2002-03-05 | 2006-11-21 | Cleveland State University | Agglomerated particles for aerosol drug delivery |
| DE60309300T3 (de) | 2002-03-20 | 2011-02-24 | Elan Pharma International Ltd. | Nanopartikelzusammensetzungen von angiogeneseinhibitoren |
| EP1501483A2 (en) | 2002-04-25 | 2005-02-02 | Nektar Therapeutics UK Ltd | Particulate materials |
| AU2003231134A1 (en) * | 2002-04-26 | 2003-11-10 | Teva Pharmaceutical Industries, Ltd. | Microparticle pharmaceutical compositions for intratumoral delivery |
| US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
| CN1255394C (zh) * | 2002-06-24 | 2006-05-10 | 成都思摩纳米技术有限公司 | 紫杉醇纳米微粒的制备方法及应用 |
| KR100573289B1 (ko) | 2002-07-20 | 2006-04-24 | 대화제약 주식회사 | 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법 |
| AU2003304108B2 (en) | 2002-10-30 | 2007-03-22 | Spherics, Inc. | Nanoparticulate bioactive agents |
| KR100508518B1 (ko) | 2002-11-13 | 2005-08-17 | 한미약품 주식회사 | 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체 |
| AU2003299590B8 (en) | 2002-12-09 | 2010-04-08 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
| US7455797B2 (en) | 2003-02-28 | 2008-11-25 | Ferro Corporation | Method and apparatus for producing particles using supercritical fluid |
| KR100849911B1 (ko) | 2003-04-03 | 2008-08-04 | 제시 엘. 에스. 에이유 | 종양-표적화 약물-로딩된 입자 |
| US20060147535A1 (en) * | 2003-04-16 | 2006-07-06 | Poongunran Muthukumaran | Methods for and compositions of anticancer medicaments |
| US20050059613A1 (en) | 2003-07-08 | 2005-03-17 | Bahram Memarzadeh | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
| US8021831B2 (en) | 2003-08-25 | 2011-09-20 | Board Of Regents, The University Of Texas System | Taxane chemosensitivity prediction test |
| JP2007001865A (ja) * | 2003-09-16 | 2007-01-11 | Ltt Bio-Pharma Co Ltd | 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤 |
| ES2574231T3 (es) | 2003-10-15 | 2016-06-16 | Syncore Biotechnology Co., Ltd | Uso de liposomas catiónicos que comprenden paclitaxel |
| US7208106B2 (en) | 2003-10-24 | 2007-04-24 | Ferro Corporation | Method of forming particles |
| CA2544627A1 (en) | 2003-11-05 | 2005-05-19 | Elan Pharma International Ltd. | Nanoparticulate compositions having a peptide as a surface stabilizer |
| GB0402963D0 (en) | 2004-02-11 | 2004-03-17 | Univ Nottingham | Counter current mixing device for two different fluids |
| US8043631B2 (en) | 2004-04-02 | 2011-10-25 | Au Jessie L S | Tumor targeting drug-loaded particles |
| JP5164381B2 (ja) | 2004-10-29 | 2013-03-21 | 株式会社奈良機械製作所 | 微細粒子の造粒方法 |
| JP2008523151A (ja) | 2004-12-14 | 2008-07-03 | トランセイブ， インク． | 生理活性物質を含む脂質粒子、その調製法及び使用法 |
| ES2265262B1 (es) | 2005-01-31 | 2008-03-01 | Activery Biotech, S.L.(Titular Al 50%) | Procedimiento para la obtencion de sistemas micro- y nanodispersos. |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| EP1855659A2 (en) * | 2005-02-24 | 2007-11-21 | Elan Pharma International Limited | Nanoparticulate formulations of docetaxel and analogues thereof |
| US7872050B2 (en) | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| CN101160116B (zh) | 2005-03-31 | 2011-12-07 | 利德斯公司 | 基于局部递送活性物质治疗前列腺疾病的方法 |
| CN1923189A (zh) | 2005-08-30 | 2007-03-07 | 孔庆忠 | 一种紫杉碱类抗癌药物的缓释注射剂 |
| AU2006284657B2 (en) | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US7829598B2 (en) | 2005-12-11 | 2010-11-09 | Scf Technologies A/S | Production of nanosized materials |
| US8906392B2 (en) | 2005-12-16 | 2014-12-09 | University Of Kansas | Nanocluster compositions and methods |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| CN101336899A (zh) | 2006-01-25 | 2009-01-07 | 济南帅华医药科技有限公司 | 含紫杉烷的抗癌缓释注射剂 |
| WO2007104549A2 (en) | 2006-03-14 | 2007-09-20 | Lidds Ab | Bioresorbable controlled-release composition |
| JP4705691B2 (ja) | 2006-10-11 | 2011-06-22 | クリティテック・インコーポレイテッド | 使用のための容器に小さい医薬粒子を沈殿させるための方法 |
| TWI405590B (zh) | 2007-04-06 | 2013-08-21 | Activus Pharma Co Ltd | 微粉碎化有機化合物粒子之製法 |
| EP3326630A3 (en) | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| WO2009006590A2 (en) | 2007-07-04 | 2009-01-08 | Dr. Reddy's Laboratories Ltd. | Docetaxel process and polymorphs |
| CN101129338A (zh) | 2007-08-27 | 2008-02-27 | 四川大学 | 超临界流体新技术微细化抗癌药物紫杉醇 |
| EP2262537A1 (en) | 2008-03-06 | 2010-12-22 | Nitto Denko Corporation | Polymer paclitaxel conjugates and methods for treating cancer |
| RU2535017C2 (ru) | 2008-09-19 | 2014-12-10 | Активус Фарма Ко., Лтд. | Композитный порошок из органического вещества для применения в медицине, способ его получения и его суспензия |
| EP2367535B1 (en) | 2008-12-02 | 2017-02-22 | Biocompatibles Uk Ltd. | Pancreatic tumour treatment |
| PT104693B (pt) | 2009-07-27 | 2011-11-24 | Univ Lisboa | Nanopartículas lipídicas semi-sólidas contendo um agente antineoplásico e seu processo de preparação |
| EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| CN101829061A (zh) * | 2010-05-14 | 2010-09-15 | 无锡纳生生物科技有限公司 | 一种紫杉醇纳米颗粒组合物及其制备方法 |
| PH12012502378A1 (en) | 2010-06-02 | 2013-02-11 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| EP2618845B1 (en) | 2010-09-21 | 2020-02-26 | Cristal Delivery B.V. | Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith |
| US20150093440A1 (en) | 2010-10-15 | 2015-04-02 | Glaxo Group Limited | Aggregate nanoparticulate medicament formulations, manufacture and use thereof |
| WO2012096995A2 (en) | 2011-01-11 | 2012-07-19 | Boston Scientific Scimed, Inc. | Coated medical devices |
| JP6038881B2 (ja) | 2011-04-20 | 2016-12-07 | ザ・ユニバーシティ・オブ・シドニー | 治療の方法及びそのために有用な剤 |
| WO2013052158A2 (en) | 2011-04-26 | 2013-04-11 | William Marsh Rice University | Targeted nanovectors and their use for treatment of brain tumors |
| MY183615A (en) | 2011-06-17 | 2021-03-03 | Berg Llc | Inhalable pharmaceutical compositions |
| CN103764172A (zh) | 2011-06-27 | 2014-04-30 | 科里斯塔鲁传送有限公司 | 控释系统 |
| FR2980683B1 (fr) | 2011-09-30 | 2014-11-21 | Univ Paris Curie | Dispositif de guidage d'un instrument medical insere dans une voie naturelle ou une voie artificielle d'un patient |
| CN102488682A (zh) | 2011-11-22 | 2012-06-13 | 四川九章生物化工科技发展有限公司 | 绿原酸的抗癌新用途 |
| US10555911B2 (en) | 2012-05-04 | 2020-02-11 | Yale University | Highly penetrative nanocarriers for treatment of CNS disease |
| TW201408304A (zh) | 2012-08-31 | 2014-03-01 | Cathay General Hospital | 一種合併抗癌藥物及荷爾蒙之抗腎細胞癌藥物及其製造方法 |
| WO2014046983A1 (en) | 2012-09-21 | 2014-03-27 | Intensity Therapeutic | Method of treating cancer |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6067892B2 (ja) * | 2013-02-28 | 2017-01-25 | ファイザー・インク | 安定性を増強した新規な液体組成物 |
| US9925512B2 (en) | 2013-03-14 | 2018-03-27 | Crititech, Inc. | Equipment assembly for and method of processing particles |
| US8778181B1 (en) | 2013-03-14 | 2014-07-15 | Crititech, Inc. | Equipment assembly for and method of processing particles |
| WO2014155146A1 (en) | 2013-03-28 | 2014-10-02 | Bbs Nanotechnology Llc | Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it |
| US9301926B2 (en) | 2013-04-10 | 2016-04-05 | Massachusetts Institute Of Technology | Local drug delivery devices and methods for treating cancer |
| EP3057619A1 (en) | 2013-10-16 | 2016-08-24 | Université Libre de Bruxelles | Formulations useful in the treatment of proliferative diseases affecting the respiratory tract |
| EP3680254A1 (en) | 2013-12-17 | 2020-07-15 | F. Hoffmann-La Roche AG | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
| NZ721908A (en) | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
| WO2015103005A1 (en) | 2014-01-03 | 2015-07-09 | Research Institute At Nationwide Children's Hospital | Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers |
| TWI601542B (zh) | 2014-04-18 | 2017-10-11 | 林信湧 | 一種用於治療肺癌之吸入式醫藥組成物及其備製方法 |
| US20150342872A1 (en) | 2014-06-01 | 2015-12-03 | Crititech, Inc. | Use of Paclitaxel Particles |
| US11033620B2 (en) | 2014-06-09 | 2021-06-15 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells and microtubules |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| US10751319B2 (en) | 2015-06-04 | 2020-08-25 | Crititech, Inc. | Collection device and methods for use |
| CN108778244B (zh) | 2015-09-16 | 2022-04-01 | Dfb索里亚有限责任公司 | 药物纳米颗粒的递送及其使用方法 |
| JP6877049B2 (ja) | 2015-09-25 | 2021-05-26 | ゼットワイ セラピューティクス インク．Ｚｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 多糖類−ビタミン共役体を含む粒状物に基づく薬物製剤 |
| DE202016006620U1 (de) | 2015-10-28 | 2017-04-12 | Qass Gmbh | Vorrichtungen zum Beobachten eines Magnetfelds eines Materialvolumens |
| WO2017127729A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| WO2017176628A1 (en) | 2016-04-04 | 2017-10-12 | Crititech, Inc. | Methods for solid tumor treatment |
| CN107281502B (zh) | 2016-04-05 | 2021-05-04 | 上海市肿瘤研究所 | 一种复合显影温敏凝胶栓塞剂、制备方法及其应用 |
| WO2017178585A1 (en) | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| ES2937291T3 (es) | 2016-09-01 | 2023-03-27 | Mayo Found Medical Education & Res | Composiciones de agentes que se unen al transportador PD-L1 y métodos de uso de las mismas para tratar cánceres |
| WO2018170210A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes |
| CN118948828A (zh) | 2017-03-15 | 2024-11-15 | Dfb索里亚有限责任公司 | 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法 |
| WO2018170207A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes |
| CN110730679A (zh) | 2017-06-09 | 2020-01-24 | 克里蒂泰克公司 | 囊内注射抗肿瘤颗粒治疗上皮囊肿 |
| CN110799176A (zh) | 2017-06-14 | 2020-02-14 | 克里蒂泰克公司 | 治疗肺部疾病的方法 |
-
2017
- 2017-04-03 WO PCT/US2017/025718 patent/WO2017176628A1/en not_active Ceased
- 2017-04-03 JP JP2018550571A patent/JP6970683B2/ja active Active
- 2017-04-03 ES ES17721227T patent/ES2858092T3/es active Active
- 2017-04-03 DK DK17721227.1T patent/DK3439635T3/da active
- 2017-04-03 KR KR1020187029173A patent/KR102317108B1/ko active Active
- 2017-04-03 BR BR112018069628-5A patent/BR112018069628A2/pt not_active IP Right Cessation
- 2017-04-03 CN CN202210381307.5A patent/CN114767860A/zh active Pending
- 2017-04-03 KR KR1020207033947A patent/KR102490665B1/ko active Active
- 2017-04-03 CN CN201780027094.3A patent/CN109475492B/zh active Active
- 2017-04-03 PT PT177212271T patent/PT3439635T/pt unknown
- 2017-04-03 RU RU2018132595A patent/RU2737934C2/ru active
- 2017-04-03 EP EP17721227.1A patent/EP3439635B1/en active Active
- 2017-04-03 EP EP20212301.4A patent/EP3854381A1/en not_active Withdrawn
- 2017-04-03 SG SG11201808125RA patent/SG11201808125RA/en unknown
- 2017-04-03 SG SG10201913409VA patent/SG10201913409VA/en unknown
- 2017-04-03 CA CA3018989A patent/CA3018989A1/en active Pending
- 2017-04-03 KR KR1020237001586A patent/KR20230017354A/ko not_active Withdrawn
- 2017-04-03 AU AU2017246316A patent/AU2017246316B2/en active Active
-
2018
- 2018-09-20 US US16/136,502 patent/US10391090B2/en active Active
-
2019
- 2019-07-15 US US16/512,044 patent/US11033542B2/en active Active
- 2019-12-13 US US16/714,099 patent/US10874660B2/en active Active
- 2019-12-13 US US16/714,151 patent/US10894045B2/en active Active
-
2020
- 2020-04-03 US US16/839,737 patent/US11458133B2/en active Active
-
2021
- 2021-10-29 JP JP2021177057A patent/JP2022009707A/ja active Pending
-
2022
- 2022-09-12 US US17/931,468 patent/US12390459B2/en active Active
- 2022-10-26 AU AU2022259773A patent/AU2022259773A1/en not_active Abandoned